In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients. Some background B-NHL is a type of...
Read More
In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL). This study concluded that this combination was safe and effective in these...
Read More
In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma. This study concluded that this treatment path is feasible and a good treatment alternative for these patients. Some background Allogenic...
Read More
In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable). The details For B-cell NHL which has relapsed (returned) after...
Read More
In a nutshell The study evaluated the outcomes of immunoglobulin replacement (IgR) therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) and immunodeficiency, who were previously treated with rituximab (Rituxan). The authors found that IgR was safe and effective to increase serum immunoglobulins in such patients. Some background B-NHL happens...
Read More
In a nutshell This initial study looked at using CAR T cells with two targets to treat relapsed B cell non-Hodgkin lymphoma (NHL). It found that this type of immunotherapy was safe and effective, and may cause less inflammation than other types of CAR T cell treatment. Some background Chimeric antigen receptor T (CAR T) cells are a treatment for...
Read More
In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....
Read More
In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...
Read More
In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...
Read MoreIn a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...
Read MoreIn a nutshell This study examined how common side effects of the heart, including heart failure, were among patients with non-Hodgkin lymphoma who received CHOP or R-CHOP chemotherapy. The results showed that only a minority developed side effects and that older patients and female patients were more likely to develop them. Some background Both...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read More
